Literature DB >> 10155328

The Short-Form 36 (SF-36) Health Survey and its use in pharmacoeconomic evaluation.

J Brazier1.   

Abstract

The Short-Form 36 (SF-36) Health Survey is a brief self-administered questionnaire that generates scores across 8 dimensions of health. It has been found to be reliable, and valid in terms of criteria such as agreement with clinical diagnosis and disease severity, but its underlying values have not been tested against patient preferences. The SF-36 was not devised for use in economic evaluation. The SF-36 may be used in cost-minimisation analyses, where the dimension scores can be shown to reflect people's values for health at an ordinal level, but it cannot be used in either cost-effectiveness or cost-utility analyses. The dimensions scores of zero to 100 do not provide a common currency and, where there is conflict between the dimension scores, there is no basis for establishing an overall health benefit. Furthermore, in clinical trials, the usual comparison is between mean or median scores, which assumes risk neutrality and does not take adequate account of the relationship between the value of health and time. Although they are under pressure to assess the cost effectiveness of healthcare interventions, researchers and policy analysts must resist short-cut methods of deriving a single index from the SF-36 that are based on arbitrary aggregation schemes, because these ignore people's preferences and the crucial quantity/quality trade-off, and therefore cannot be used in economic evaluations. However, the rich descriptive material and multidimensionality of the SF-36 may have potential for use in economic evaluation. Multi-attribute utility theory provides a way of deriving a single index based on elicited values, but it requires a major restructuring of the scales of the SF-36. Alternatively, SF-36 responses may provide material for constructing health scenarios that could then be valued on a holistic basis.

Entities:  

Mesh:

Year:  1995        PMID: 10155328     DOI: 10.2165/00019053-199507050-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  36 in total

1.  Cost-effectiveness guidelines for reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status?

Authors:  M Drummond
Journal:  Health Econ       Date:  1992-07       Impact factor: 3.046

Review 2.  The use of QALYs in health care decision making.

Authors:  G Loomes; L McKenzie
Journal:  Soc Sci Med       Date:  1989       Impact factor: 4.634

3.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

Review 4.  Standards for validating health measures: definition and content.

Authors:  J E Ware
Journal:  J Chronic Dis       Date:  1987

5.  The MOS short-form general health survey. Reliability and validity in a patient population.

Authors:  A L Stewart; R D Hays; J E Ware
Journal:  Med Care       Date:  1988-07       Impact factor: 2.983

6.  Overview of adult health measures fielded in Rand's health insurance study.

Authors:  R H Brook; J E Ware; A Davies-Avery; A L Stewart; C A Donald; W H Rogers; K N Williams; S A Johnston
Journal:  Med Care       Date:  1979-07       Impact factor: 2.983

Review 7.  Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life.

Authors:  D A Revicki; R M Kaplan
Journal:  Qual Life Res       Date:  1993-12       Impact factor: 4.147

8.  A health-related quality of life instrument for patients evaluated for epilepsy surgery.

Authors:  B G Vickrey; R D Hays; J Graber; R Rausch; J Engel; R H Brook
Journal:  Med Care       Date:  1992-04       Impact factor: 2.983

9.  Toward clinical applications of health status measures: sensitivity of scales to clinically important changes.

Authors:  R A Deyo; T S Inui
Journal:  Health Serv Res       Date:  1984-08       Impact factor: 3.402

10.  Performance of a five-item mental health screening test.

Authors:  D M Berwick; J M Murphy; P A Goldman; J E Ware; A J Barsky; M C Weinstein
Journal:  Med Care       Date:  1991-02       Impact factor: 2.983

View more
  13 in total

Review 1.  Pharmaceutical care programmes for the elderly: economic issues.

Authors:  Grainne E Crealey; Ian K Sturgess; James C McElnay; Carmel M Hughes
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

2.  Nighttime insomnia symptoms and perceived health in the America Insomnia Survey (AIS).

Authors:  James K Walsh; Catherine Coulouvrat; Goeran Hajak; Matthew D Lakoma; Maria Petukhova; Thomas Roth; Nancy A Sampson; Victoria Shahly; Alicia Shillington; Judith J Stephenson; Ronald C Kessler
Journal:  Sleep       Date:  2011-08-01       Impact factor: 5.849

3.  Using the SF-36 and Euroqol on an elderly population.

Authors:  J E Brazier; S J Walters; J P Nicholl; B Kohler
Journal:  Qual Life Res       Date:  1996-04       Impact factor: 4.147

4.  Psychometric properties of the incontinence utility index among patients with idiopathic overactive bladder: data from two multicenter, double-blind, randomized, Phase 3, placebo-controlled clinical trials.

Authors:  Nacho Castejón; Kristin Khalaf; Quanhong Ni; Jesús Cuervo; Donald L Patrick
Journal:  Health Qual Life Outcomes       Date:  2015-08-01       Impact factor: 3.186

Review 5.  Growth hormone therapy and quality of life in adults and children.

Authors:  Deborah J Radcliffe; Joseph S Pliskin; J B Silvers; Leona Cuttler
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

6.  Cost-effectiveness of an integrated 'fast track' rehabilitation service for multi-trauma patients involving dedicated early rehabilitation intervention programs: design of a prospective, multi-centre, non-randomised clinical trial.

Authors:  Sevginur Kosar; Henk Am Seelen; Bena Hemmen; Silvia Maa Evers; Peter Rg Brink
Journal:  J Trauma Manag Outcomes       Date:  2009-01-30

7.  Importance of sociodemographic and morbidity aspects in measuring health-related quality of life: performances of three tools: comparison of three questionnaire scores.

Authors:  Cecilia Quercioli; Gabriele Messina; Emanuela Barbini; Giovanni Carriero; Mara Fanì; Nicola Nante
Journal:  Eur J Health Econ       Date:  2008-12-09

8.  Economic evaluation of brief psychodynamic interpersonal therapy in patients with multisomatoform disorder.

Authors:  Nadja Chernyak; Heribert Sattel; Marsel Scheer; Christina Baechle; Johannes Kruse; Peter Henningsen; Andrea Icks
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

Review 9.  The current practice of handling and reporting missing outcome data in eight widely used PROMs in RCT publications: a review of the current literature.

Authors:  Ines Rombach; Oliver Rivero-Arias; Alastair M Gray; Crispin Jenkinson; Órlaith Burke
Journal:  Qual Life Res       Date:  2016-01-28       Impact factor: 4.147

10.  The Effectiveness and Cost-Effectiveness of Spinal Cord Stimulation for Refractory Angina (RASCAL Study): A Pilot Randomized Controlled Trial.

Authors:  Sam Eldabe; Simon Thomson; Rui Duarte; Morag Brookes; Mark deBelder; Jon Raphael; Ed Davies; Rod Taylor
Journal:  Neuromodulation       Date:  2015-09-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.